AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8578768 — intervention group
Group type: EXPERIMENTAL
Intervention: DV‐7751a 800 mg
Number of subjects: 0
Study 8578768 — intervention group
Group type: EXPERIMENTAL
Intervention: DV‐7751a
Number of subjects: 0
Study 2121802 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam
Number of subjects: 0
Study 2121802 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 0
Study 2121802 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 421671 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg xipamide daily
Number of subjects: 16
Study 421671 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg xipamide daily
Number of subjects: 16
Study 421671 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dosages of xipamide
Number of subjects: 16
Study 421671 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythrocyte deformability
Number of subjects: 16
Study 31635815 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron 25mg and 50mg
Number of subjects: 0
Study 31635815 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimuscarinics (solifenacin 2.5, 5, and 10mg; tolterodine 4mg)
Number of subjects: 0
Study 31635815 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30883864 — intervention group
Group type: COMPARATOR
Intervention: LSD (100 μg)
Number of subjects: 27
Study 27693447 — intervention group
Group type: EXPERIMENTAL
Intervention: Retropubic urethral sling placement
Number of subjects: 203
Study 27693447 — intervention group
Group type: COMPARATOR
Intervention: No sling placement
Number of subjects: 203
Study 26072330 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon α (IFNα)
Number of subjects: 0
Study 26072330 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyurea
Number of subjects: 0
Study 24079847 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation intervention involving practice and feedback with cross-examination questions
Number of subjects: 164
Study 24079847 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 164
Study 21400127 — intervention group
Group type: EXPERIMENTAL
Intervention: Vessel sealing system uvulopalatoplasty (VSSU)
Number of subjects: 31
Study 21400127 — intervention group
Group type: COMPARATOR
Intervention: Uvulopalatal flap (UPF)
Number of subjects: 31
Study 19781211 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg (high dose)
Number of subjects: 150
Study 19781211 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 10 mg (low dose)
Number of subjects: 150
Study 16504645 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple risk factor intervention (MRFI) program
Number of subjects: 200
Study 16504645 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 200
Study 16504645 — intervention group
Group type: EXPERIMENTAL
Intervention: MRFI program
Number of subjects: 200
Study 16504645 — intervention group
Group type: EXPERIMENTAL
Intervention: MRFI program and Conventional care
Number of subjects: 200
Study 15246125 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise training (RET)
Number of subjects: 155
Study 15246125 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 155
Study 11059437 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus bi‐weekly automated assessment and self‐care education calls with telephone follow‐up by a nurse educator
Number of subjects: 280
Study 11059437 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 280
Study 9082038 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans fatty acids (elaidic acid at 5.5% energy)
Number of subjects: 27
Study 9082038 — intervention group
Group type: EXPERIMENTAL
Intervention: 16:0-rich fats
Number of subjects: 27
Study 9082038 — intervention group
Group type: EXPERIMENTAL
Intervention: cis 18:1
Number of subjects: 27
Study 9082038 — intervention group
Group type: COMPARATOR
Intervention: 16:0 and cis 18:1
Number of subjects: 27
Study 8358980 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily dosing of methotrexate (2.5mg oral daily doses, totaling 15 mg weekly)
Number of subjects: 20
Study 8358980 — intervention group
Group type: COMPARATOR
Intervention: Weekly dosing of methotrexate (15 mg)
Number of subjects: 20
Study 3526734 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 120 mg/day (6 X 20 mg)
Number of subjects: 14
Study 3526734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 3526734 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN)
Number of subjects: 14
Study 3526734 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 14
Study 29863691 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellex (0.1 mg daily for 10 days)
Number of subjects: 52
Study 29863691 — intervention group
Group type: COMPARATOR
Intervention: Basic therapy (control group)
Number of subjects: 52
Study 27167103 — intervention group
Group type: EXPERIMENTAL
Intervention: ivabradine and beta-blockers
Number of subjects: 71
Study 27167103 — intervention group
Group type: COMPARATOR
Intervention: beta-blockers alone
Number of subjects: 71
Study 24309322 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with 5-fluorouracil and leucovorin
Number of subjects: 143
Study 24309322 — intervention group
Group type: COMPARATOR
Intervention: Surveillance only
Number of subjects: 143
Study 23106925 — intervention group
Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 81
Study 23106925 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 81
Study 20863926 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 45
Study 20863926 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol + Prostatic Plexus Block
Number of subjects: 45
Study 20863926 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol + Fentanyl
Number of subjects: 45
Study 18037940 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDC) with cyclophosphamide 6000 mg/m(2) and thiotepa 800 mg/m(2) (CHUT) and stem cell support
Number of subjects: 308
Study 18037940 — intervention group
Group type: COMPARATOR
Intervention: No further treatment (observation)
Number of subjects: 308
Study 18037940 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDC) with CHUT
Number of subjects: 308
Study 15728054 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 64
Study 15728054 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 64
Study 12623421 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (involved field doses range from 40 to 48 Gy, median 44.5 Gy)
Number of subjects: 130
Study 12623421 — intervention group
Group type: COMPARATOR
Intervention: Combined therapy (radiotherapy followed by chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone, by six cycles)
Number of subjects: 130
Study 10390385 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapering of inhaled corticosteroids (fluticasone propionate) at weekly intervals
Number of subjects: 28
Study 8875517 — intervention group
Group type: EXPERIMENTAL
Intervention: Omegavenous 10% (fish oil)
Number of subjects: 0
Study 8875517 — intervention group
Group type: COMPARATOR
Intervention: Liposyn III 10% (control)
Number of subjects: 0
Study 1994595 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial fundoplication (180‐200 degrees, Toupet)
Number of subjects: 71
Study 1994595 — intervention group
Group type: COMPARATOR
Intervention: Total fundoplication (360 degrees, Rossetti)
Number of subjects: 71
Study 6339985 — intervention group
Group type: EXPERIMENTAL
Intervention: Pergolide
Number of subjects: 25
Study 6339985 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 31368057 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat 40 mg
Number of subjects: 57
Study 31368057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 27555294 — intervention group
Group type: EXPERIMENTAL
Intervention: Asparaginase treatment
Number of subjects: 31
Study 27555294 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant dexamethasone therapy
Number of subjects: 31
Study 27703033 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-Only (VO) training
Number of subjects: 1464
Study 27703033 — intervention group
Group type: COMPARATOR
Intervention: Video Self-Instruction kit (VSI) training
Number of subjects: 1464
Study 24735134 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 495
Study 24735134 — intervention group
Group type: COMPARATOR
Intervention: Multiple daily injections (MDI)
Number of subjects: 495
Study 24735134 — intervention group
Group type: EXPERIMENTAL
Intervention: CSII
Number of subjects: 495
Study 22780999 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g/day ginseng
Number of subjects: 40
Study 22780999 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g/day ginseng
Number of subjects: 40
Study 22780999 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.5 g/day ginseng
Number of subjects: 40
Study 22780999 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 19534023 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan 16 mg/d for 2 months
Number of subjects: 26
Study 19534023 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 17024220 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative steroid drops
Number of subjects: 40
Study 17024220 — intervention group
Group type: COMPARATOR
Intervention: Single sub‐tenon injection of triamcinolone
Number of subjects: 40
Study 15042637 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver skill‐building (CSB) treatment intervention
Number of subjects: 0
Study 15042637 — intervention group
Group type: COMPARATOR
Intervention: Information and support only (ISO) control intervention
Number of subjects: 0
Study 11710414 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 10-minute bouts of walking (N = 5)
Number of subjects: 30
Study 11710414 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 30-minute bout of continuous walking (N = 6)
Number of subjects: 30
Study 11710414 — intervention group
Group type: COMPARATOR
Intervention: Non-exercising group (N = 7)
Number of subjects: 30
Study 11710414 — intervention group
Group type: EXPERIMENTAL
Intervention: Both exercise groups (3 10-minute bouts and 1 30-minute bout)
Number of subjects: 30
Study 9643274 — intervention group
Group type: EXPERIMENTAL
Intervention: moexipril 15 mg
Number of subjects: 97
Study 9643274 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ) 25 mg
Number of subjects: 97
Study 7836708 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal control and euglycaemia
Number of subjects: 6
Study 7836708 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinsulinaemia
Number of subjects: 6
Study 7836708 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycaemia
Number of subjects: 6
Study 3414729 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg phenylpropanolamine
Number of subjects: 6
Study 3414729 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg phenylpropanolamine plus 400 mg caffeine
Number of subjects: 6
Study 3414729 — intervention group
Group type: COMPARATOR
Intervention: 75 mg phenylpropanolamine
Number of subjects: 6
Study 3414729 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31982647 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral activation intervention administered in a 16-week freshman orientation course
Number of subjects: 540
Study 31982647 — intervention group
Group type: COMPARATOR
Intervention: Standard orientation course
Number of subjects: 540
Study 30489436 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning to Live with Cancer (LTLWC) intervention program (BCIG, n = 30)
Number of subjects: 52
Study 30489436 — intervention group
Group type: COMPARATOR
Intervention: Control group (BCCG, n = 22)
Number of subjects: 52
Study 28606731 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher urine albumin-creatinine ratio (ACR)
Number of subjects: 2800
Study 28606731 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower estimated glomerular filtration rate (eGFR)
Number of subjects: 2800
Study 28606731 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher urine ACR
Number of subjects: 2800
Study 25514515 — intervention group
Group type: EXPERIMENTAL
Intervention: iTBS (intermittent theta burst stimulation) applied daily over dPMCright during a four-day hand training program using mirror training (MT) for 20 minutes daily.
Number of subjects: 0
Study 25514515 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (control group CG) during the same four-day hand training program using mirror training (MT) for 20 minutes daily.
Number of subjects: 0
Study 23948646 — intervention group
Group type: EXPERIMENTAL
Intervention: Kiosk with attached devices for healthy eating/weight monitoring
Number of subjects: 51
Study 23948646 — intervention group
Group type: COMPARATOR
Intervention: General health/BP monitoring (attention-control)
Number of subjects: 51
Study 21564047 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg methylprednisolone acetate with 20 ml levobupivacaine 0.125%
Number of subjects: 33
Study 21564047 — intervention group
Group type: COMPARATOR
Intervention: 80 mg methylprednisolone acetate with 20 ml levobupivacaine 0.125%
Number of subjects: 33
Study 17881183 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (Tam) alone
Number of subjects: 489
Study 17881183 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic Tamoxifen (8 weeks) and Megestrol acetate (MA) (8 weeks) for 2 years
Number of subjects: 489
Study 16501401 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care intervention (n = 160)
Number of subjects: 324
Study 16501401 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 164)
Number of subjects: 324
Study 15164911 — intervention group
Group type: EXPERIMENTAL
Intervention: Home polysomnography
Number of subjects: 64
Study 15164911 — intervention group
Group type: COMPARATOR
Intervention: Laboratory polysomnography
Number of subjects: 64
Study 12213869 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg/d)
Number of subjects: 40
Study 12213869 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 9810030 — intervention group
Group type: EXPERIMENTAL
Intervention: Boswellia serrata gum resin 300 mg thrice daily for 6 weeks
Number of subjects: 40
Study 9810030 — intervention group
Group type: COMPARATOR
Intervention: Lactose 300 mg thrice daily for 6 weeks (Control)
Number of subjects: 40
Study 7704170 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma outreach program
Number of subjects: 53
Study 2667311 — intervention group
Group type: EXPERIMENTAL
Intervention: urapidil (60 mg twice daily)
Number of subjects: 295
Study 2667311 — intervention group
Group type: COMPARATOR
Intervention: captopril (25 mg twice daily)
Number of subjects: 295
Study 4694405 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural block
Number of subjects: 0
Study 4694405 — intervention group
Group type: COMPARATOR
Intervention: General anaesthetic alone
Number of subjects: 0
Study 31454356 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-quantity lipid-based nutrient supplements (SQ-LNSs) provided monthly during screenings.
Number of subjects: 2330
Study 31454356 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior change communication (BCC) on nutrition, health, and hygiene practices.
Number of subjects: 2330
Study 27977231 — intervention group
Group type: EXPERIMENTAL
Intervention: African American Dementia Caregiver Problem Inventory (DCPI‐A)
Number of subjects: 0
Study 25936784 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Ca (needle aperture directed caudally)
Number of subjects: 82
Study 25936784 — intervention group
Group type: COMPARATOR
Intervention: Group Ce (needle aperture oriented in a cephalad direction)
Number of subjects: 82
Study 24152981 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 9014
Study 24152981 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9014
Study 21600552 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan-coated polyglactin 910 sutures
Number of subjects: 450
Study 21600552 — intervention group
Group type: COMPARATOR
Intervention: Polyglactin 910 sutures (Control)
Number of subjects: 450
Study 19390547 — intervention group
Group type: EXPERIMENTAL
Intervention: XELOX
Number of subjects: 0
Study 19390547 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX-4
Number of subjects: 0
Study 16393432 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide/timolol fixed combination (DTFC)
Number of subjects: 22
Study 16393432 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost 0.005%
Number of subjects: 22
Study 15246460 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-deoxyglucose (2-DG) 40 mg/kg, i.v.
Number of subjects: 28
Study 15246460 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (HV)
Number of subjects: 28
Study 11734428 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% saline
Number of subjects: 20
Study 11734428 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 20
Study 9231871 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-minute training session on facial movements
Number of subjects: 75
Study 9231871 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 75
Study 7695928 — intervention group
Group type: EXPERIMENTAL
Intervention: Antegrade cardioplegia
Number of subjects: 101
Study 7695928 — intervention group
Group type: COMPARATOR
Intervention: Combined cardioplegia
Number of subjects: 101
Study 3024828 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen B (cyclophosphamide, doxorubicin, vincristine, and etoposide)
Number of subjects: 116
Study 3024828 — intervention group
Group type: COMPARATOR
Intervention: Regimen A (cyclophosphamide, doxorubicin, and vincristine)
Number of subjects: 116
Study 31157522 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise combined with radiofrequency (temperature maintained between 40°C and 42°C)
Number of subjects: 28
Study 31157522 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (radiofrequency power of 0 W)
Number of subjects: 28
Study 31157522 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise combined with radiofrequency
Number of subjects: 28
Study 30482135 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm fluid bolus (500 mL of Ringer's acetate at 38°C)
Number of subjects: 21
Study 30482135 — intervention group
Group type: COMPARATOR
Intervention: Cold fluid bolus (500 mL of Ringer's acetate at 22°C)
Number of subjects: 21
Study 28225050 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B12 supplementation
Number of subjects: 91
Study 25166221 — intervention group
Group type: EXPERIMENTAL
Intervention: BF Spiromax 160+9 μg b.i.d.
Number of subjects: 75
Study 25166221 — intervention group
Group type: EXPERIMENTAL
Intervention: Symbicort Turbohaler 200+12 μg b.i.d.
Number of subjects: 75
Study 25166221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 23040144 — intervention group
Group type: EXPERIMENTAL
Intervention: CapOpus plus TAU
Number of subjects: 103
Study 23040144 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 103
Study 21387002 — intervention group
Group type: EXPERIMENTAL
Intervention: Enumeration task (Experiment 1)
Number of subjects: 0
Study 21387002 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection task (Experiment 2)
Number of subjects: 0
Study 21387002 — intervention group
Group type: EXPERIMENTAL
Intervention: Specified number detection task (Experiment 3)
Number of subjects: 0
Study 18328845 — intervention group
Group type: EXPERIMENTAL
Intervention: Early exercise stress testing (EST) after coronary stenting
Number of subjects: 1000
Study 16339195 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 nM folic acid (FA)
Number of subjects: 39
Study 16339195 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 nM folic acid (FA)
Number of subjects: 39
Study 16339195 — intervention group
Group type: EXPERIMENTAL
Intervention: 240 nM folic acid (FA)
Number of subjects: 39
Study 14618461 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition intervention (NI; n=15)
Number of subjects: 36
Study 14618461 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC; n=21)
Number of subjects: 36
Study 10916717 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day family medicine preceptorship
Number of subjects: 137
Study 9136305 — intervention group
Group type: EXPERIMENTAL
Intervention: Orem‐based nursing care promoting nutritional self-care, provided in patients' homes the week after discharge.
Number of subjects: 104
Study 9136305 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 104
Study 1358821 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 0
Study 1358821 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethendine maleate
Number of subjects: 0
Study 1358821 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine and Dimethendine maleate
Number of subjects: 0
Study 6142067 — intervention group
Group type: EXPERIMENTAL
Intervention: Desensitization to sulfasalazine
Number of subjects: 47
Study 31412770 — intervention group
Group type: EXPERIMENTAL
Intervention: QLB group (0.4 cc/kg of 0.3% ropivacaine)
Number of subjects: 60
Study 31412770 — intervention group
Group type: COMPARATOR
Intervention: C group (0.4 cc/kg of 0.9% saline)
Number of subjects: 60
Study 31412770 — intervention group
Group type: EXPERIMENTAL
Intervention: QLB group
Number of subjects: 60
Study 29943093 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa/carbidopa (100/25 mg)
Number of subjects: 70
Study 29943093 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 27765726 — intervention group
Group type: EXPERIMENTAL
Intervention: Trospium chloride (30 mg/250 ml) gastric infusion for 6 hours
Number of subjects: 0
Study 27765726 — intervention group
Group type: EXPERIMENTAL
Intervention: Trospium chloride (30 mg) immediate-release tablets
Number of subjects: 0
Study 27765726 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric infusion of trospium chloride
Number of subjects: 0